What Happened?

After the market closed on August 6, 2025, a large block trade of 194,510 shares (₩7.8 billion) of Kolon TissueGene stock occurred. Institutional investors were net buyers at ₩7.9 billion, while foreign investors were net sellers at ₩1.2 billion.

Why Did This Happen?

Institutional buying is interpreted as reflecting positive factors such as expectations for the TG-C Phase 3 clinical trial and improvements in the company’s financial structure. On the other hand, foreign selling may be attributed to profit-taking following the recent stock price increase, concerns about the uncertainty of clinical trial results, or other supply and demand factors. After-hours block trading is the result of a complex interplay of intentions from various market participants, so it is difficult to interpret it solely in one direction.

What’s Next?

The future stock price of Kolon TissueGene will largely depend on the results of the TG-C Phase 3 clinical trial and FDA approval. In the short term, volatility may increase due to the impact of this block trade, but in the medium to long term, the clinical trial results will be the key factor determining the stock’s direction.

What Should Investors Do?

Investors should closely monitor the progress of the TG-C clinical trial and news related to FDA approval. It is crucial to develop an investment strategy based on the company’s fundamentals and long-term growth potential, rather than being swayed by short-term stock price fluctuations. In particular, risk factors such as high accumulated deficit and litigation risks should be carefully evaluated.